<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Iranian Journal of Toxicology</title>
<title_fa>مجله سم شناسی و مسمومیتهای ایران</title_fa>
<short_title>IJT</short_title>
<subject>Medical Sciences</subject>
<web_url>http://ijt.arakmu.ac.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2008-2967</journal_id_issn>
<journal_id_issn_online>2251-9459</journal_id_issn_online>
<journal_id_pii>8</journal_id_pii>
<journal_id_doi>10.22034/IJT</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>14</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>13</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1386</year>
	<month>6</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2007</year>
	<month>9</month>
	<day>1</day>
</pubdate>
<volume>1</volume>
<number>3</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa>Acute Liver Dysfunction Associated With Interferon-Beta-1a (Avonex®) Use in A Young Female Patient with Relapsing-Remitting Multiple Sclerosis (RRMS)</title_fa>
	<title>Acute Liver Dysfunction Associated With Interferon-Beta-1a (Avonex®) Use in A Young Female Patient with Relapsing-Remitting Multiple Sclerosis (RRMS)</title>
	<subject_fa>عمومى</subject_fa>
	<subject>General</subject>
	<content_type_fa>پژوهشي</content_type_fa>
	<content_type>Research</content_type>
	<abstract_fa></abstract_fa>
	<abstract>
&lt;span style=&quot;font-weight: bold&quot;&gt;Background:&lt;/span&gt; It has been reported that liver function alterations occur in 8–38% of patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon-beta in controlled clinical trials or in prospective but non-controlled studies. We report herein a case of symptomatic liver dysfunction associated with two-year-period of regular interferon-beta-1a (Avonex®) intramuscular injections in a young female patient with relapsing-remitting multiple sclerosis.
 &lt;br&gt;&lt;span style=&quot;font-weight: bold&quot;&gt;Case:&lt;/span&gt; The patient was 19 year-old female with clinically proved RRMS, treated with interferon-beta-1a (Avonex®) 30 µg weekly by intramuscular injections for two years. She was referred with clinical symptoms of liver dysfunction including abdominal peri-umbilical and right upper quadrant pain, anorexia and malaise, that constipation, dark urine and icterus. Laboratory studies corroborated acute hepatitis state without any viral, autoimmune or drug-related causes. Patient's status improved after two weeks of conservative therapy and withholding interferon. Billirubin, liver function tests and liver enzyme values returned to normal. 
&lt;br&gt;&lt;span style=&quot;font-weight: bold&quot;&gt;Conclusion:&lt;/span&gt; Interferon-beta compounds could have serious hepatic complications, and patients using interferon-beta-1a should regularly monitor their liver function. 


</abstract>
	<keyword_fa>Interferon-Beta-1a, Avonex®, Relapsing-Remitting Multiple Sclerosis (RRMS), Acute Liver Dysfunction</keyword_fa>
	<keyword>Interferon-Beta-1a, Avonex®, Relapsing-Remitting Multiple Sclerosis (RRMS), Acute Liver Dysfunction</keyword>
	<start_page>8</start_page>
	<end_page>8</end_page>
	<web_url>http://ijt.arakmu.ac.ir/browse.php?a_code=A-10-2-66&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Ali Reza </first_name>
	<middle_name></middle_name>
	<last_name>Rezaei Ashtiani</last_name>
	<suffix></suffix>
	<first_name_fa>علیرضا</first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa>رضایی آشتیانی</last_name_fa>
	<suffix_fa></suffix_fa>
	<email>r110_ashtiani@yahoo.com</email>
	<code>10031947532846003477</code>
	<orcid>10031947532846003477</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Department of Neurology, Vali-E-Asr. Medical Center,Arak Medical university, Arak, Iran</affiliation>
	<affiliation_fa>Department of Neurology, Vali-E-Asr. Medical Center,Arak Medical university, Arak, Iran</affiliation_fa>
	 </author>


	<author>
	<first_name>Babak </first_name>
	<middle_name></middle_name>
	<last_name>Zamani</last_name>
	<suffix></suffix>
	<first_name_fa>بابک</first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa>زمانی</last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>10031947532846003478</code>
	<orcid>10031947532846003478</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Neurology,Rasol-e-Akram Medical Center, Tehran, Iran</affiliation>
	<affiliation_fa>Department of Neurology,Rasol-e-Akram Medical Center, Tehran, Iran</affiliation_fa>
	 </author>


	<author>
	<first_name>Mohammad</first_name>
	<middle_name></middle_name>
	<last_name>Rohani</last_name>
	<suffix></suffix>
	<first_name_fa>محمد</first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa>روحانی</last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>10031947532846003479</code>
	<orcid>10031947532846003479</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Neurology,Rasol-e-Akram Medical Center, Tehran, Iran</affiliation>
	<affiliation_fa>Department of Neurology,Rasol-e-Akram Medical Center, Tehran, Iran</affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
